Computer technology giant has announced grants and in-kind contributions valued at more than $10 million to ten nonprofit organizations in support of children's cancer research and care.
Through its initiative, the company awarded grants to eight organizations in support of efforts to address the physical, mental, and emotional needs of young cancer patients as they undergo treatment. The recipients include in Paris, which was awarded a grant to launch "CREA FORM" in its pediatric department as a way to keep children connected to their peers and studies during cancer treatment; the in Chengu, China, which received a grant to provide free leukemia treatment to children who have successfully completed their first year of therapy but are likely to discontinue therapy for monetary reasons; and Illinois-based , which was awarded a grant to offer "home away from home" services to families who've had to travel for their child's cancer treatment.
The company also announced that it would provide cloud-computing technology to the and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) to enable doctors to collaborate virtually, identify personalized treatments, and begin administering care within days — a process that in the past took months. And to mark National Childhood Cancer Awareness Month in September, the company collaborated with to raise awareness of deadly disease neuroblastoma, the most common form of cancer in infants, and announced that it would donate $1 to NMTRC, up to $30,000, for every person who views a video at to learn how technology is accelerating pediatric cancer treatment.
"Every day in a child's life is precious — that's why technology that can accelerate cancer treatment is so important," said Dell vice president for corporate responsibility Trisa Thompson. "We're honored to bring our technology, team member support and funding to help the fight against childhood cancer. In partnership with families, nonprofits, and the medical community, we know Dell can make a difference."